We hypothesize that integrating PSMA-derived features—such as the intraprostatic maximum standardized uptake value (SUVmax)—alongside established clinical risk factors into an LR model and an ML-derived PGM improves the prediction of early PCa progression in patients after primary treatment. This evidence concerns the gene FOLH1 and posterior cortical atrophy.